Business
NuGen M.D. Welcomes Greg Gironda to its Advisory Board
TORONTO, ON / ACCESSWIRE / September 16, 2022 / NuGen Medical Devices Inc. (TSXV:NGMD)(OTC...

About this update from Nugen Medical Devices Inc
[{"type":"text","content":"NuGen M.D. Welcomes Greg Gironda to its Advisory BoardTORONTO, ON / ACCESSWIRE / September 16, 2022 / NuGen Medical Devices Inc. (TSXV:NGMD)(OTCQB:NGMDF) (\"NuGen'' or the \"Company\"), a leader in needle-free drug delivery, is pleased to announce the appointment of Greg Gironda to the Company's Advisory Board.Greg Gironda has over 30 years of pharmaceutical and biotechnology experience. Currently, Greg is the managing partner of Pharmacense, a company that provides corporate development and strategic planning services for life science companies. Prior to Pharmacense, Greg held various strategic planning and business development roles at companies like King Pharmaceuticals, Labopharm, EMD Serono, Neura Therapeutik, and Genentech.\"Greg brings a wealth of experience in needle-free and pharmaceutical technology to the table, making him an ideal fit for our Company as we continue to develop next-generation needle-free injection devices,\" said Michael Wright, CEO of NuGen. \"His addition as an advisor is evidence of NuGen's focus on enhancing and broadening the skillset of its advisory team.\"While at Serono (EMD Serono), Greg was the first to launch a combination needle-free device, cool.click and a biologic, Saizen recombinant growth hormone. To support this combination, Greg established a team of reimbursement specialists called Connections for Growth, the GHMonitor, a clinical registry for patients on Saizen and cool.click and the Nurse Network, a team of nurses throughout the U.S. that trained both pediatric endocrinology nurses and Saizen patients. He also developed extensive training materials on the use of the cool.click needle-free device and a direct-to-patient campaign.With the introduction of the cool.click and Saizen combination, Greg was able to grow Saizen's market share from <1.0% to 20% even though Saizen was the fifth entry into the growth hormone market and was competing against notable growth hormone competitors like Genentech, Eli Lilly, Novo Nordisk and Pharmacia (now a part of Pfizer). He also went on to assist Serono's affiliate countries in launching cool.click in Europe and Asia.About NuGen Medical DevicesNuGen is an emerging specialty medical device company developing the next generation of needle-free technologies and other innovative medical delivery products. The company's products, which include th...